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Background: Although knowledge of the genetics of diffuse large B-cell lymphoma (DLBCL) has been increasing,
little is known about the characteristics and prognostic significance of cytogenetic abnormalities and the clinical
utility of cytogenetic studies performed on bone marrow (BM) specimens. To investigate the significance of isolated
cytogenetic aberrations in the absence of histologic BM involvement, we assessed the implication of cytogenetic
staging and prognostic stratification by a retrospective multicenter analysis of newly diagnosed DLBCL patients.
Methods: We analyzed cytogenetic and clinical data from 1585 DLBCL patients whose BM aspirates had been
subjected to conventional karyotyping for staging. If available, interphase fluorescence in situ hybridization (FISH)
data were also collected from patients.
Results: Histologic BM involvement were found in 259/1585 (16.3%) patients and chromosomal abnormalities
were detected in 192 (12.1%) patients (54 patients with single abnormalities and 138 patients with 2 or more
abnormalities). Isolated cytogenetic aberrations (2 or more abnormalities) without histologic involvement were
found in 21 patients (1.3%). Two or more cytogenetic abnormalities were associated with inferior overall survival
(OS) compared with a normal karyotype or single abnormality in both patients with histologic BM involvement
(5-year OS, 16.5% vs. 52.7%; P < 0.001) and those without BM involvement (31.8% vs. 66.5%; P < 0.001). This result
demonstrated that BM cytogenetic results have a significant prognostic impact that is independent of BM histology.
The following abnormalities were most frequently observed: rearrangements involving 14q32, 19q13, 19p13, 1p,
3q27, and 8q24; del(6q); dup(1q); and trisomy 18. In univariate analysis, several specific abnormalities including
abnormalities at 16q22-q24, 6p21-p25, 12q22-q24, and −17 were associated with poor prognosis. Multivariate
analyses performed for patients who had either chromosomal abnormalities or histologic BM involvement, revealed
IPI high risk, ≥ 2 cytogenetic abnormalities, and several specific chromosomal abnormalities, including abnormalities
at 19p13, 12q22-q24, 8q24, and 19q13 were significantly associated with a worse prognosis.
(Continued on next page)* Correspondence: csuh@amc.seoul.kr; soonlee@plaza.snu.ac.kr
7Department of Internal Medicine, Asan Medical Center, University of Ulsan
College of Medicine, 86 Asanbeongwon-gil, Songpa-gu, Seoul 138-736,
Republic of Korea
1Department of Laboratory Medicine, Seoul National University Hospital,
Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu,
Seoul 110-744, Republic of Korea
Full list of author information is available at the end of the article
© 2013 Kim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kim et al. Journal of Hematology & Oncology 2013, 6:76 Page 2 of 16
http://www.jhoonline.org/content/6/1/76(Continued from previous page)
Conclusions: We suggest that isolated cytogenetic aberrations can be regarded as BM involvement and
cytogenetic evaluation of BM improves staging accuracy along with prognostic information for DLBCL patients.
Keywords: Diffuse large B-cell lymphoma, Cytogenetics, Chromosomal abnormalities, Bone marrow
involvement, PrognosisIntroduction
Bone marrow (BM) evaluations are an essential part of
the routine staging of diffuse large B-cell lymphoma
(DLBCL) [1]. DLBCL with BM involvement is rated as
Ann Arbor stage IV, resulting in higher International
Prognostic Index (IPI) scores and, thus, poor prognoses
[2]. BM has traditionally been evaluated by morphological
examination, which commonly includes immunohisto-
chemical (IHC) staining. Histologic BM involvement
has been reported in 10-30% of DLBCL cases [3,4].
Recently, additional efforts have been made to detect
even a minimal involvement of lymphoma cells using
flow cytometry and molecular or cytogenetic techniques.
With the application of these complementary tests,
approximately 10-20% of cases that were initially classified
as histologically negative have been reassessed as having
BM involvement [5-7]. In a previous study in which BM
was evaluated using flow cytometry and immunoglobulin
gene rearrangement analysis, a change in IPI was noted
in 11.5% on immunophenotyping alone, and 14.1%
cases on immunophenotyping and molecular testing.
The revised IPI model using immunophenotyping pro-
vided better differentiation between the IPI prognostic
categories [6].
Classical cytogenetic studies of BM specimens play a
pivotal role in the diagnosis and prognostic prediction
of many hematologic malignancies. However, the cyto-
genetic data concerning DLBCL tissues are limited.
DLBCL is a group of B-cell malignancies that are ex-
tremely heterogeneous histopathologically, biologically,
and clinically. Consistent with this heterogeneity, vari-
ous chromosomal abnormalities have been reported in
patients with DLBCL [8]. Correlations between cyto-
genetic data and clinical outcomes have been attempted
for DLBCL; however, controversy remains concerning
the prognostic significance of these data, most of which
were obtained before the initiation of R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednis-
olone) therapy.
In Korea, cytogenetic studies of BM specimens using
the G-banding technique have been a routine practice
in many hospitals, primarily to aid in the detection of
BM involvement when staging newly diagnosed DLBCL
patients. Cytogenetic study of the BM can overcome the
limitations of tumor tissue cytogenetics such as fuzzy
chromosomes, failure in obtaining cells in metaphase, andcontamination. The presence of chromosomal aberrations
in the absence of histologic involvement of BM raises the
question as to whether the abnormalities truly originate
from BM involving-lymphoma cells or if the aberrations
are just cytogenetic noise. In the present study, to investi-
gate the characteristics of chromosomal aberrations in
the BM of DLBCL patients and to determine their
prognostic significance, we retrospectively analyzed
cytogenetic data of BM specimens submitted for sta-
ging from a large series of DLBCL patients.
Materials and methods
Study population
A total of 1585 DLBCL cases were referred from six
tertiary hospitals in Korea: Seoul National University
Hospital (n = 646; 1996 to 2011); Asan Medical Center
(n = 484; 2001 to 2009); National Cancer Center of
Korea (n = 236; 2004 to 2009); Yonsei University Hospital
(n = 118; 2004 to 2009); Hallym University Hospital
(n = 57; 2004 to 2009); and Korea Cancer Center Hospital
(n = 44; 2005 to 2009). The cases were selected on the
basis of diagnoses established according to the 2008
World Health Organization (WHO) classification criteria
for primary tissue biopsy specimens [9]. BM biopsies were
conducted for staging purposes at the time of the initial
diagnosis. The treatment protocols were heterogeneous
but generally conformed to international standards,
including combination chemotherapy using CHOP-like
regimens for front-line therapy, as well as salvage
chemotherapy followed by stem cell transplantation for
refractory cases. The baseline patient characteristics are
summarized in Table 1. All of the patients were Korean,
and the median age was 57 years (range, 2–91 years). A
total of 1128 patients (71.2%) received R-CHOP as the
initial therapy, 380 patients (24.0%) received a therapy
other than R-CHOP (157 CHOP and 223 other regimens),
and 77 patients (4.9%) received an unknown treatment
or no treatment. The median follow-up time was
25.7 months (range, 0.1-211.1 months).This study was
reviewed and approved by the institutional review
board of each hospital.
Histopathology
A primary DLBCL diagnosis was established by examining
hematoxylin and eosin (H&E)-stained sections of diagnos-
tic biopsies from various tissues with IHC stains, including
Table 1 The baseline characteristics of 1585 DLBCL patients and a comparison of the clinical features of the patients
with histologic BM involvement (BMIhisto
+) and those without (BMIhisto
–)
Characteristics Total BMIhisto
+ BMIhisto
– P value*
(n = 1585) (n = 259) (n = 1326)
Median age, years (range) 57.4 (1.9-90.9) 59.0 (1.9-86.4) 57.0 (5.3-90.9) 0.013
Age > 60 yr 679/1585 (42.8) 124/259 (47.9) 555/1326 (41.9) 0.073
Gender (male/female, %male) 881/704 (55.6) 132/127 (51.0) 749/577 (56.5) 0.102
B symptoms 394/1585 (24.9) 135/259 (52.1) 259/1326 (19.5) <0.001
ECOG≥ 2 226/1585 (14.3) 86/259 (33.2) 140/1326 (10.6) <0.001
High serum LDH 975/1585 (61.5) 203/259 (78.4) 772/1326 (58.2) <0.001
Stage 3 or 4 822/1585 (52.6) 259/259 (100) 574/1326 (43.3) <0.001
Stage 3 or 4, excluding BM status 809/1585 (51.0) 237/259 (91.5) 572/1326 (43.1) <0.001
Extranodal involvement≥ 2 sites 497/1585 (31.4) 193/259 (74.5) 304/1326 (22.9) <0.001
International Prognostic Index
Low risk 392/1585 (24.7) 0/259 (0) 392/1326 (29.6) <0.001
Low/intermediate risk 462/1585 (29.2) 33/259 (12.7) 427/1326 (32.4)
High/intermediate risk 467/1585 (29.5) 114/259 (44.0) 353/1326 (26.6)
High risk 264/1585 (16.7) 112/259 (43.2) 152/1315 (11.5)
Non-GCB type 500/877 (57.0) 95/150 (63.3) 405/727 (55.7) 0.086
CD5-positive 33/341 (9.7) 7/57 (12.3) 26/284 (9.2) 0.466
Initial treatment
R-CHOP 1128/1585 (71.2) 146/259 (56.4) 982/1326 (74.1) <0.001
CHOP 157/1585 (9.9) 30/259 (11.6) 127/1326 (9.6)
Other treatment 223/1585 (14.1) 53/259 (20.5) 170/1326 (12.8)
No therapy 77/1585 (4.9) 30/259 (11.6) 47/1326 (3.5)
Initial treatment response
CR 1020/1394 (73.2) 118/207 (57.0) 902/1187 (76.0) <0.001
PR 268/1394 (19.2) 51/207 (24.6) 217/1187 (18.3)
SD 33/1394 (2.4) 8/207 (3.9) 25/1187 (2.1)
PD 73/1394 (5.2) 30/207 (14.5) 43/1187 (3.6)
Follow-up data
Deaths 484/1585 (30.5) 134/259 (51.7) 350/1326 (26.4) <0.001
Median follow-up, months (range) 25.7 (0.1-211.1) 12.0 (0.1-141.4) 29.5 (0.1-211.1) <0.001
*P value are based on the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables.
The data represent the median (range) for continuous variables or the number (percentage) for categorical variables, unless otherwise indicated.
Abbreviations: BMI, bone marrow involvement; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB,
germinal center B-cell-like; LDH, lactic dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; PD, progressive disease;
PR, partial remission; SD, stable disease.
Kim et al. Journal of Hematology & Oncology 2013, 6:76 Page 3 of 16
http://www.jhoonline.org/content/6/1/76CD3, CD20, CD5, CD10, BCL2, BCL6, and IRF/MUM1,
according to the diagnostic protocol of each institute.
The type of DLBCL based on the cell of origin, either
germinal center B-cell-like (GCB) or non-GCB, was
defined in 877 cases using the algorithm of Hans et al.
[10]. In general, the BM biopsies were performed bilat-
erally. Wright-stained BM smears and H&E-stained
sections of BM biopsies were reviewed by hematopatho-
logists at each institute. IHC staining was performed at
the discretion of hematopathologists at each institute.
The BM reports were reviewed centrally, and additionalIHC staining targeting CD3, CD20, and CD79a was
performed for cases with discrepant results between
histologic examination and cytogenetic tests, to confirm
the initial BM histologic diagnosis. The presence of benign
lymphoid aggregates was distinguished from lymphoma
involvement using previously described criteria [11]. Flow
cytometric analysis was performed for some cases with
diffuse infiltration of lymphoma cells (n = 46). According
to the BM results, the cases were dichotomized into those
with histological BM involvement (BMIhisto
+) and those
without (BMIhisto
−).
Kim et al. Journal of Hematology & Oncology 2013, 6:76 Page 4 of 16
http://www.jhoonline.org/content/6/1/76Cytogenetic analysis of BM
Conventional cytogenetic tests using the G-banding
technique were performed on BM aspirates from all the
patients. The cytogenetic tests were performed locally,
and the reports were reviewed centrally by two of the
investigators (SYK and DSL). Cytogenetic studies using
standard techniques were performed as a part of the
diagnostic work-up at the time of initial diagnosis. Con-
ventional G-banding cytogenetic analysis was performed
using the short-term unstimulated culture (24–48 h) of
BM cells. At least 20 metaphases were analyzed, whenever
possible. Clonal abnormalities were defined as at least two
cells with the same aberration if the aberration is a chromo-
some gain or a structural rearrangement, or 3 or more cells
with the same chromosome missing. The karyotypes were
recorded according to the International System for Human
Cytogenetic Nomenclature (ISCN) [12]. We classified the
karyotype results according to the complexity of the
chromosomal abnormalities observed. A complex karyo-
type was defined as ≥ 3 chromosomal abnormalities, in
accordance with previous studies [13,14]. A monosomal
karyotype was defined as either a single autosomal mono-
somy in the presence of one or more structural aberration
or two or more distinct autosomal chromosome mono-
somies [15,16]. In the interpretation of specific abnor-
malities, numerical aberrations included gains, losses of
chromosomes (aneuploidy) and changes in ploidy. Struc-
tural aberrations included abnormalities such as deletions,
translocations, isochromosomes, and duplications. Trans-
locations included balanced reciprocal translocations and
translocations with unknown partners (additions).
Fluorescence in situ hybridization (FISH) was perfor-
med in some cases (n = 235). The following target regions
were investigated using the accompanying probes: 14q32/
IGH using an IGH dual-color, break-apart rearrangement
probe (n = 201); cMYC/IGH using a dual-color, dual-
fusion probe (n = 11); BCL2/IGH using a dual-color, dual-
fusion probe (n = 29); 9p21/p16 using a p16/CEP 9
dual-color probe (n = 178); 3q27/BCL6 using a BCL6
dual-color, break-apart rearrangement probe (n = 95);
8q24/cMYC using a cMYC break-apart probe (n = 39) or
a cMYC/IGH using dual-color, dual-fusion probe (n = 11);
1q25 using a 1p32/1q25 probe (n = 49); 17p13/TP53
using a P53 probe (n = 34); and 18q23/BCL2 using a
BCL2/IGH dual-color, dual-fusion probe (n = 29; all
probes from Abbott/Vysis, Downers Grove, IL, USA). We
analyzed interphase cells according to the manufacturer’s
instruction and the ISCN criteria. At least 200 nuclei per
sample were scored for normal or abnormal FISH signals.
The normal cut-off values for translocation, deletion, or
amplification were based on the mean (± 3SD) and the bi-
nomial distribution function [17] analyzed of 40 negative
controls. The cut-off values for IGH break-apart probe
was 2%, and cMYC/IGH probe was < 0.5%.Statistical analyses
The data were compared using the Mann–Whitney and
Kruskal-Wallis tests for continuous variables and χ2 test
for categorical variables. Each numerical abnormality
and the specific locus of each structural abnormality
were dichotomized as present or absent, and hierarchical
clustering was performed using Pearson correlation dis-
tance metrics and Wald linkage tests. The probabilities
of overall survival (OS) and progression-free survival
(PFS) [18] were plotted according to the Kaplan-Meier
method, and the log-rank test with Bonferroni correction
for multiple testing was used to compare the survival
curves. A multivariate analysis was performed using the
Cox regression method. The following parameters were
analyzed for multivariate analysis: advanced age, gender,
IPI risk groups, history of R-CHOP treatment, BMIhisto
+
vs BMIhisto
−, ≥ 2 abnormalities vs normal karyotype or
1 abnormality, and presence of several specific cytogenetic
abnormalities abnormalities, which were associated with
poor prognosis in univariate analysis and found in a
minimum of 5 patients. Variables in the final model were
selected using stepwise selection procedure with a thresh-
old of P = 0.05. The statistical analyses were performed
using SPSS version 15 (SPSS, Chicago, IL, USA) and
the R statistical package (R Development Team 2012).
A probability level of 0.05 was considered significant in
the univariate analysis. When multiple hypothesis testing
was performed, the P value was adjusted by Bonferroni
correction.
Results
Comparison of histology and conventional cytogenetic
tests for the detection of BM involvement
A total of 259 patients (16.3%) had BM involvement, as
determined through histologic examinations. Among the
259 BMIhisto
+ patients, 181 (69.9%) exhibited lymphoma
cells on BM aspirate smears, and all 259 patients dem-
onstrated lymphoma involvement in a BM biopsy. The
median percentage of lymphoma cells in the BM aspir-
ate smear was 6.2% (range, 0-98%). Compared with the
BMIhisto
– group, the BMIhisto
+ group had a poorer per-
formance status, higher lactate dehydrogenase (LDH)
levels, more advanced stage tumors, and more prevalent
extranodal involvement; consequently, these patients had
higher IPI scores (Table 1).
Chromosomal abnormalities were detected in 192/
1585 patients (12.1%), of whom 124/192 (64.6%) were
BMIhisto
+ (Table 2). Among the 192 patients with chromo-
somal aberrations, 42 (21.9%) exhibited the following
single numerical aberrations: 33 patients had Y chromo-
some loss; 7 patients had a loss or gain of other single
chromosomes; and 2 patients had hyperdiploid clones
(Additional file 1: Table S1). Among the 42 patients with
the above single numerical aberrations, 4/42 (9.5%) were
Table 2 A comparison of the histologic and conventional cytogenetic analyses
Cytogenetic findings No. of
patients
No. of
BMIhisto
+
cases
Percentage of abnormal metaphases BM
lymphoma
cell
percentage†
BMIhisto
+ BMIhisto
− P value*
Normal karyotype 1393 (87.9) 135/1393 (9.7) NA NA NA 1 (0–98)
Abnormal karyotype 192 (12.1) 124/192 (64.6) 49 (8–100) 25 (5–100) < 0.001 18 (0–95)
Single abnormality 54 (3.4) 7/54 (13.0) 35 (8–100) 25 (9–100) 0.697 5 (0–86)
Single numerical abnormality 42 (2.6) 4/42 (9.5) 60 (27–100) 21 (10–100) 0.038 3 (0–86)
Loss of Y 33 (2.1) 3/33 (9.1) 70 (50–100) 20 (10–100) 0.021 6 (0–86)
Loss of another single chromosome 7 (0.4) 1/7 (14.3) 27 22 (15–70) 0.617 0‡
Polyploidy 2 (0.1) 0/2 (0) NA 27 (22–31) NA NA
Single structural abnormality 12 (0.8) 3/12 (25.0) 15 (8–35) 67 (9–100) 0.090 5 (0–29)
Multiple abnormalities 138 (8.8) 117/138 (84.8) 50 (8–100) 25 (5–100) 0.009 19 (0–95)
2 abnormalities 10 (0.7) 6/10 (60.0) 67 (10–100) 23 (15–58) 0.394 41 (12–73)
1 structural and 1 numerical abnormality 6 (0.4) 4/6 (66.7) 67 (13–92) 39 (20–58) 0.355 27 (12–50)
2 structural abnormalities 4 (0.3) 2/4 (50.0) 55 (10–100) 20 (15–25) 0.999 61 (49–73)
≥ 3 abnormalities 128 (8.1) 111/128 (86.7) 48 (8–100) 30 (5–100) 0.024 18 (0–95)
(complex karyotype)
*P value by the Mann–Whitney U test comparing the percentage of abnormal metaphases between the BMIhisto
+ and BMIhisto
− groups.
†Lymphoma cell percentage calculated from bone marrow aspirate smears.
‡This case showed diffuse DLBCL involvement in the bone marrow biopsy.
The data represent the median (range) for continuous variables or the number (percentage) for categorical variables, unless otherwise indicated.
Abbreviations: BMIhisto
+, histologic bone marrow involvement; BMIhisto
−, no evidence of histologic bone marrow involvement; NA, not applicable.
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+, which was not significantly different from the
proportion of BMIhisto
+ patients with normal karyotypes
(135/1393, 9.7%; P = 0.971). There were 12 patients
with single structural abnormalities, of whom 4 patients
exhibited single deletions [del(13q) in 2 patients and
del(20)(q11.2) in 2 patients], and 1 patient had a dupli-
cation of Y chromosome; none were BMIhisto
+. Seven
patients exhibited translocations, including t(2;11)(p21;
q23), t(4;10)(q28;p13), t(6;18)(p23;p11), t(10;11)(q22;q23),
add(12)(q24), t(3;14)(q27;q32), and t(14;18)(q32;q21);
the patients with the latter 3 types of abnormalities
were BMIhisto
+. The remaining 138/192 patients (71.9%)
exhibited ≥ 2 aberrations. Ten of these patients exhibited 2
chromosomal abnormalities: 6 patients had 1 structural
aberration and 1 numerical aberration, and 4 patients had
2 structural aberrations. Among the patients with 2
chromosomal abnormalities, 6/10 (60%) were BMIhisto
+. A
total of 128 patients exhibited complex karyotypes. Many
of these patients had highly complex abnormalities, with a
median of 9 total chromosomal abnormalities (range, 3–
25) including many structural abnormalities (median, 7;
range, 0–20). Among the patients with complex karyo-
types, 111/128 were BMIhisto
+ (86.7%). Consequently, 117/
138 patients (84.8%) with ≥ 2 chromosomal aberrations
were BMIhisto
+. Among the patients with complex karyo-
types, the percentages of abnormal metaphases were higher
in the BMIhisto
+ group compared with the BMIhisto
− group
(P = 0.024). The percentages of metaphases with Y
chromosome losses were higher in the BMIhisto
+ group
(P = 0.021), however, there was no significant differences
in the number of metaphases for patients with loss of
single chromosomes other than Y, polyploidy or single
structural abnormalities between the BMIhisto
+ and
BMIhisto
− groups. Among the patients with complex karyo-
types, only a weak correlation was found between the per-
centage of metaphases with aberrant karyotypes and the
percentage of lymphoma cells in BM aspirates (r = 0.365).
Our results indicate that a finding of BM cytogenetic aber-
rations involving single numerical abnormalities alone can-
not be regarded as sufficient evidence of BM involvement
of lymphoma cells, considering the low concordance be-
tween such findings and the histologic results. If multiple
chromosomal abnormalities were considered as definite
evidence of the presence of lymphoma cells, the 21/1585
(1.3%) patients with isolated cytogenetic aberrations with-
out histologic involvement would be reassessed as having
BM involvement.
Chromosomal abnormalities and clinical and biological
characteristics
We compared the clinical and biological characteristics
of the BMIhisto
+ patients with normal karyotypes to pa-
tients with abnormal karyotypes. Compared with the pa-
tients with normal karyotypes, the patients with a singlenumerical abnormality presented with less aggressive
disease, as evidenced by their lower LDH levels, less in-
volvement of extranodal sites, and lower IPI risk scores.
In contrast, the patients with ≥ 2 chromosomal abnor-
malities had a poorer performance status, higher LDH
levels, more advanced disease stages, more prevalent
extranodal involvement, and thus, higher IPI scores
(Table 3).
Comparison of BM histology and FISH results
The histologic examinations, conventional cytogenetics,
and FISH results of a limited number of patients were
compared (Table 4). Among the 235 patients for whom
FISH studies were performed, there were 3 BMIhisto
− pa-
tients with normal karyotypes and abnormal 14q32/IGH
FISH results, although the frequencies of abnormal FISH
signals were low (5%, 7%, and 8%). A single BMIhisto
− pa-
tient exhibited cytogenetic abnormalities of the 8q24
locus despite normal FISH results using a specific probe.
Characteristics of cytogenetic aberrations
We analyzed the frequencies of specific cytogenetic ab-
errations among the patients with chromosomal aberra-
tions other than single numerical aberrations (n = 150)
(Figure 1). The chromosomes most frequently involved
were chromosome 1, 3, 6, 14, and 18. The most com-
mon numerical aberrations were trisomy 18, trisomy 7,
trisomy 3, loss of Y, and loss of 13. The predominant
structural aberrations involved the following loci:
rearrangements involving 14q32, 19q13, 19p13, 1p32-
p36, 3q27, 8q24, 18q21-q23, 1cen-1q12, 9p22-p24,
11q23-q25, 16q22-q24, and; deletions of 6q; and duplica-
tions of 1q. The well-known oncogenes and lymphoma-
related genes that exhibited frequent breakpoints, in-
cluding BCL6 (3q27), JAK2 (9p22), IGH (14q32), and
BCL2 (18q21), as well as other possible oncogenes with
breakpoints, are indicated in Figure 1D. Monosomal kar-
yotypes were observed in 70 patients (46.7%), and
hyperdiploidy was noted in 24 cases (16.0%). Reciprocal
translocations were observed in 90 patients (60.0%); among
them, 19 carried reciprocal translocations involving the
14q32/IGH region with defined partners. The transloca-
tion partners were the following: t(8;14)(q24;q32) in 5
cases; t(14;18)(q32;q21) in 4 cases; t(3;14)(q27;q32) in 3
cases; t(1;14)(q21;q32); t(1;14)(q25;q32); t(3;14)(p25;q32); t
(6;14)(q25;q32); t(9;14)(p13;q32); t(9;14)(q13;q32); and t
(14;19)(q32;q13).
Prognoses according to the chromosomal abnormalities
and BM histology
We analyzed the prognostic impacts of chromosomal ab-
normalities according to the complexity of the chro-
mosomal aberrations involved (Figure 2). There was a
significant difference in prognosis between patients with ≥ 2
Table 3 A comparison of the clinical and laboratory characteristics of patients with histologic BMI (BMIhisto
+) with
normal karyotypes and patients with chromosomal abnormalities
Parameters BMIhisto
+ and normal karyotype Abnormal karyotypes
(n = 135) 1 numerical 1 structural ≥ 2 abnormalities
(n = 42) (n = 12) (n = 138)
Age (years)
Median (range) 58 (2–86) 67 (11–83) * 56 (45–77) 60 (10–86)
Age > 60 yr 64/135 (47.4) 34/42 (81.0) * 5/12 (41.7) 66/138 (47.8)
Gender (male/female) 59/76 (43.7) 35/7 (83.3) * 10/2 (83.3) * 76/62 (55.1)
ECOG≥ 2 26/135 (19.3) 6/42 (14.3) 0/12 (0) 62/138 (44.9) *
High serum LDH 95/135 (70.4) 16/42 (38.1) * 6/12 (50.0) 123/138 (89.1) *
B symptoms 50/135 (37.0) 7/42 (16.7) * 6/12 (50.0) 98/138 (71.0) *
Stage 3 or 4, 123/135 (91.1) 18/42 (42.9) * 9/12 (75.0) 126/138 (91.3)
excluding BM status
Extranodal≥ 2 sites 89/135 (65.9) 13/42 (31.0) * 5/12 (41.7) 112/138 (81.2) *
IPI risk
Low 0/135 (0) 16/42 (38.1) 1/12 (8.3) 1/138 (0.7)
Low/intermediate 28/135 (20.7) 10/42 (23.8) 5/12 (41.7) 4/138 (2.9)
High/intermediate 65/135 (48.2) 10/42 (23.8) 6/12 (50.0) 58/138 (42.0)
High 42/135 (31.1) 6/42 (14.3) * 0/12 (0) * 75/138 (54.4) *
Non-GCB type 46/73 (63.0) 17/26 (65.4) 3/8 (37.5) 53/88 (60.2)
CD5- positive 4/32 (12.5) 0/3 (0) 0/1 (0) 3/30 (10.0)
R-CHOP treatment 83/135 (61.5) 31/42 (73.8) 8/12 (66.7) 78/138 (56.5)
Death 53/135 (39.3) 10/42 (23.8) 2/12 (16.7) 90/138 (65.2) *
*Significant P value (< 0.05) for each subgroup compared with the group of BMIhisto
+ patients with normal karyotypes.
The data represent the number (percentage) for categorical variables, unless otherwise indicated.
Abbreviations: DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell-like; IPI, International Prognostic
Index; LDH, lactic dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
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http://www.jhoonline.org/content/6/1/76abnormalities and those with a normal karyotype or a single
abnormality both in the BMIhisto
+ group (5-year OS, 22.0%
vs. 52.7%; P < 0.001) and BMIhisto
− group (5-year OS, 31.8%
vs. 66.5%; P < 0.001). In BMIhisto
− groups, the patients with
a single numerical abnormality and those with singleTable 4 A comparison of conventional cytogenetic (CG) and f
FISH positve
Probe No. of
patients
BMIhisto
+ / BMIhisto
+ / BMIhisto
− / BMIhist
CGwhole
+ CGwhole
− CGwhole
+ CGwho
14q32/IGH 37/235 (15.7) 20 (54.1) 11 (29.7) 3 (8.1) 3 (8.1
9p21/p16 17/178 (9.6) 14 (82.4) 3 (17.6) 0 (0) 0 (0
3q27/BCL6 19/95 (20.0) 14 (73.7) 5 (26.3) 0 (0) 0 (0
8q24/MYC 7/50 (14.0) 5 (71.4) 2 (28.6) 0 (0) 0 (0
1p32/1q25 9/49 (18.4) 9 (100) 0 (0) 0 (0) 0 (0
17p13/TP53 3/34 (8.8) 1 (33.3) 2 (66.7) 0 (0) 0 (0
18q23/BCL2 3/29 (10.3) 0 (0) 2 (66.7) 1 (33.3) 0 (0
The data represent the number (percentage) for categorical variables.
Abbreviations: FISH, fluorescence in situ hybridization; CGwhole
+/CGwhole
−, normal or
chromosomes; CGlocus
+/CGlocus
−, normal or abnormal results of conventional cytogestructural abnormality did not exhibit significant differ-
ences in OS compared with those with normal karyo-
types (P = 0.422 and 0.137, respectively). The number of
BMIhisto
+ patients with single abnormalities was too small
to assess prognostic impact (Additional file 2: Figure S1).luorescence in situ hybridization (FISH) results
FISH negative
o
− / No. of
patients
BMIhisto
+ / BMIhisto
+ / BMIhisto
− / BMIhisto
− /
le
− CGlocus
+ CGlocus
− CGlocus
+ CGlocus
−
) 198/235 (84.3) 6 (3.0) 54 (27.3) 0 (0.0) 138 (69.7)
) 161/178 (90.4) 3 (1.9) 50 (31.1) 0 (0) 108 (67.1)
) 76/95 (80.0) 2 (2.6) 28 (36.8) 0 (0) 46 (60.5)
) 43/50 (86.0) 3 (7.0) 12 (27.9) 1 (2.3) 27 (67.8)
) 40/49 (81.6) 1 (2.5) 21 (52.5) 0 (0) 18 (45.0)
) 31/34 (91.2) 0 (0) 8 (25.8) 0 (0) 23 (74.2)
) 26/29 (89.7) 2 (7.7) 7 (26.9) 0 (0) 17 (65.4)
abnormal results of conventional cytogenetic tests considering whole
netic tests for the specific locus, which is targeted by FISH probes.
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Figure 1 (See legend on next page.)
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Figure 1 Chromosomal aberrations in patients with chromosomal aberrations except single numerical aberrations (n = 150). (A) The
frequency of the chromosomes involved. (B) The frequencies of chromosomal gains (upper bars) and losses (lower bars). (C) The frequencies of
structural aberrations in each chromosome arm (p arm, blue; q arm, red). (D) Ideograms showing the specific chromosomal aberrations. The
orange lines on the left of the ideogram indicate chromosomal losses, and the green lines on the right side indicate gains. The red lines
represent breakage points of deletions, and the blue lines indicate breakage points of chromosomal rearrangements. The thick green lines
represent duplications.
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http://www.jhoonline.org/content/6/1/76There was no significant difference in OS and PFS
according to the number of abnormalities among the pa-
tients with ≥ 2 abnormalities (Additional file 3: Figure S2).
When patients were classified according to IPI risk
groups, BMIhisto
+ patients with ≥ 2 cytogenetic abnorma-
lities presented significantly poorer prognosis compared
with normal karyotypes in the high/intermediate-risk
group (5-year OS, 35.4% vs. 69.4%, P < 0.001; Figure 3A).
BMIhisto
− patients with ≥ 2 abnormalities revealed signifi-
cantly poorer prognosis in the high/intermediate and high
risk groups (5-year OS, 31.8% vs. 58.4%, P = 0.027 for
high/intermediate risk group; 0% vs. 40.6%, P < 0.001 for
high risk group, respectively; Figure 3B).
When R-CHOP-treated patients were analyzed sepa-
rately, ≥ 2 chromosomal abnormalities were associated
with poorer prognoses compared with normal karyotypes
or 1 abnormality among both the R-CHOP-treated
BMIhisto
+ patients (5-year OS, 33.9% vs. 70.9%; P < 0.001)
xand the BMIhisto
− patients (5-year OS, 39.5% vs. 72.2%;
P = 0.003; Additional file 4: Figure S3).A
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Figure 2 Overall survival (OS) according to the chromosomal abnorm
with histologic bone marrow involvement (BMIhisto
+; n = 259) and (B) for p
n = 1326). The patients with≥ 2 chromosomal abnormalities exhibited signThe presence of a monosomal karyotype had no appar-
ent prognostic value among patients with ≥ 2 abnormalities
(5-year OS, 25.4% vs. 20.0%; P = 0.274). There was no sig-
nificant prognostic value of hyperdiploidy among patients
with ≥ 2 abnormalities (5-year OS, 24.7% vs. 23.1%; P =
0.413). Among the 877 patients for whom IHC information
was available, the non-GCB group demonstrated a lower
OS than the GCB group (5-year OS, 58.6% vs. 71.2%, re-
spectively; P = 0.004). However, among patients with ≥ 2
abnormalities, there was no significant difference in OS
between the non-GCB and GCB types (5-year OS, 25.4%
vs. 23.4%, respectively; P = 0.467).
Prognoses according to specific chromosomal abnormalities
We investigated the prognostic impacts of the specific
chromosomal abnormalities. Figure 4A presents hazard
ratios (HRs) obtained by univariate Cox analysis for OS
and PFS according to specific chromosomal abnormal-
ities found in ≥ 8 patients using BMIhisto
+ patients with
normal karyotype as a reference group among 327B
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alities and BM histology. (A) Kaplan Meier survival curves for patients
atients without histologic bone marrow involvement (BMIhisto
−;
ificantly worse survival in both the BMIhisto
+ and BMIhisto
− groups.
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Figure 3 Overall survival (OS) according to risk stratification by international prognostic index (IPI) scores and chromosomal
abnormalities. (A) Kaplan Meier survival curves for patients with histologic bone marrow involvement (BMIhisto
+; n = 259) and (B) for patients
without histologic bone marrow involvement (BMIhisto
−; n = 1326).
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http://www.jhoonline.org/content/6/1/76patients with either cytogenetic abnormalities or were
BMIhisto
+. The presence of structural abnormalities at
16q22-q24 was significantly associated with a higher risk
for both OS (HR, 5.86, P < 0.001) and disease pro-
gression (HR, 4.05, P < 0.001). The abnormalities at 6p21
(HR for OS, 4.89, P < 0.001), 12q22-q24 (HR, 4.28,
P < 0.001), and −17 (HR, 4.49, P < 0.001) were also
significant association with adverse prognosis. Consistent
results were observed in the R-CHOP-treated patients
(Additional file 5: Figure S4). In addition, frequent loci of
cytogenetic abnormalities, including 11q21-q23, 19q13,
18q21, 1q21-q23, 8q24, 19p13, 3q27, 6q, and 14q32 were
also associated with adverse outcomes.
To identify the subgroups of BM-involved DLBCL that
exhibited distinct cytogenetic aberrations, we performed
cluster analyses using the loci associated with poor sur-
vival in the univariate analysis and frequent and charac-
teristic breakpoints, including 14q32, 3q27, 8q24, 19p13,
and 19p13. Based on the hierarchical cluster analysis,
138 patients with ≥ 2 chromosomal abnormalities were
segregated into clusters with characteristic patterns of
chromosomal abnormalities (Figure 4B). When we com-
pared prognoses among the clusters, Cluster 7, which
was composed of loci associated with poorer prognoses
in the univariate analysis, revealed the poorest prognosis
(Figure 4C).Multivariate analysis of prognoses among patients with
BM abnormalities diagnosed by either histologic
examination or conventional cytogenetic testing
A multivariate analysis was performed for 327 patients
who had either chromosomal abnormalities or were
BMIhisto
+ (Table 5). When the presence of ≥ 2 cytogen-
etic abnormalities was analyzed with other covariates,
the presence of ≥ 2 cytogenetic abnormalities was also
significantly associated with a worse OS (HR, 2.49; 95%
CI, 1.75-3.54; P < 0.001). The high IPI score was strongly
associated with a poor prognosis, whereas R-CHOP
treatment was strongly associated with a better progno-
sis. When the specific chromosomal abnormalities which
were associated with adverse prognosis in the univariate
analysis were analyzed, the aberration at 19p13 was se-
lected as an independent adverse prognostic factor (HR,
2.67; 95% CI, 1.50-4.76; P = 0.001), in addition to 7q22,
12q22-q24, 18q21, and 16q22-q24. When PFS was ana-
lyzed, aberrations at 19p13 and 8q24 emerged as factors
independently associated with disease progression (HR,
3.02 and 2.61, respectively; P < 0.001 and P < 0.001, re-
spectively). When 200 R-CHOP treated patients among
327 patients were analyzed separately, 19q13 (HR, 3.36,
P = 0.003), 12q22-q24, 19p13, and 8q24 were independ-
ently predicted poor OS, and 19p13 and 8q24 were asso-
ciated with disease progression (Table 5).
A Overall survival
in patients with BMI (n = 327) 
Progression-free survival
in patients with BMI (n = 327)
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Figure 4 Prognoses according to specific chromosomal abnormalities. (A) Forest plots showing hazard ratios obtained by univariate Cox
analysis for overall survival (OS) and progression-free survival (PFS) according to the presence of specific chromosomal abnormalities using
patients with lymphoma bone marrow involvement and normal karyotype as a reference group in 327 patients having either abnormal
karyotypes or histologic BM involvement. (B) Based on a cluster analysis of 33 frequent numerical abnormalities and breakpoints, 138 patients
with≥ 2 chromosomal abnormalities were segregated into clusters with characteristic abnormality patterns. The horizontal labels indicate clusters
(red, Cluster 1; yellow, Cluster 2; green, Cluster 3; blue, Cluster 4; cyan, Cluster 5; purple, Cluster 6; and black, Cluster 7). The characteristic loci of
the abnormalities in each cluster are indicated in red, and the loci associated with a poor prognosis in the univariate analysis are indicated in
blue in the right panel. (C) The (OS) and PFS of each cluster is plotted.
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With recent advances in genetic technology, the value of
G-banding data is often underestimated compared with
the data derived from higher-resolution techniques, such
as FISH, array-CGH, and deep sequencing. Molecular
testing for immunoglobulin gene rearrangements is also
a sensitive test for detecting clonal cells within bone
marrow, which detected BM positive cases in 16% of
histologically negative cases in a previous study [6,19].
Although conventional karyotyping has low resolution,this method remains the only technique used worldwide
in many hospital laboratories; thus, it is readily applic-
able in routine practice. In addition, the advantages of
conventional cytogenetic tests include their ability to de-
tect abnormalities in proliferative clones; to provide in-
formation regarding whole chromosomes, including
balanced translocations; and to distinguish between het-
erogeneous clones that coexist in a sample.
In fact, conventional cytogenetic testing is not as
widely performed for DLBCL as for other hematologic
Table 5 Multivariate Cox analysis of the overall survival (OS) and progression-free survival (PFS) among 327 patients
having either cytogenetic abnormalities (CAs) or histologic BM involvement (BMIhisto
+) and among R-CHOP treated
patients (n = 200)*
OS PFS
Risk factors No. of patients (%) HR 95% CI P HR 95% CI P
Total patients with CAs and/or BMIhisto
+ (n = 327)
Presence of ≥ 2 cytogenetic abnormalities as a risk factor
IPI risk group, high vs. low 123 (37.6) 6.46 1.56-26.72 0.010 7.15 1.73-29.46 0.007
R-CHOP treatment, R-CHOP vs. others 200 (61.2) 0.26 0.18-0.35 <0.001 0.38 0.28-0.51 <0.001
≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality 138 (42.2) 2.49 1.75-3.54 <0.001 2.12 1.53-2.93 <0.001
Presence of specific cytogenetic abnormalities as risk factors
IPI risk group, high vs. low 123 (37.6) 8.34 2.04-24.09 0.003 8.43 2.06-34.44 0.003
R-CHOP treatment, R-CHOP vs. others 200 (61.2) 0.24 0.17-0.34 <0.001 0.32 0.24-0.44 <0.001
19p13 abnormality present vs. absent 24 (7.3) 2.67 1.50-4.76 0.001 3.02 1.85-4.93 <0.001
7q22 abnormality present vs. absent 11 (3.4) 3.03 1.51.-6.06 0.002 NS NS NS
12q22-q24 abnormality present vs. absent 12 (3.7) 2.68 1.37.-5.26 0.004 NS NS NS
18q21 abnormality present vs. absent 21 (6.4) 2.11 1.22.-3.64 0.007 NS NS NS
16q22-q24 abnormality present vs. absent 14 (4.3) 2.27 1.23-4.18 0.009 NS NS NS
11q23-q25 abnormality present vs. absent 19 (5.8) 1.81 1.03-3.15 0.038 NS NS NS
8q24 abnormality present vs. absent 19 (5.8) NS NS NS 2.61 1.54-4.43 <0.001
R-CHOP treated patients with CAs and/or BMIhisto
+ (n = 200)
Presence of ≥ 2 cytogenetic abnormalities as a risk factor
IPI risk group, high vs. low 67 (33.5) 5.29 1.23-22.86 0.026 5.55 1.32-23.37 0.020
Male vs. female 112 (56.0) 1.71 1.01-2.91 0.046 NS NS NS
≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality 78 (39.0) 2.01 1.17-3.45 0.012 2.15 1.38-3.38 0.001
Presence of specific cytogenetic abnormalities as risk factors
IPI risk group, high vs. low 67 (33.5) 5.92 1.40-25.04 0.016 7.61 1.82-31.92 0.006
Male vs. female 112 (56.0) 2.00 1.15-3.47 0.014 1.71 1.09-2.69 0.021
19q13 abnormality present vs. absent 13 (6.5) 3.36 1.50-7.54 0.003 NS NS NS
12q22-q24 abnormality present vs. absent 6 (3.0) 3.65 1.42-9.44 0.007 NS NS NS
19p13 abnormality present vs. absent 16 (8.0) 2.85 1.20-6.80 0.018 3.31 1.68-6.51 0.001
8q24 abnormality present vs. absent 13 (6.5) 2.54 1.24-5.23 0.011 2.43 1.24-4.73 0.009
*The multivariate Cox regression models initially included age, gender, the International Prognostic Index (IPI) risk groups, history of R-CHOP treatment, presence of
histologic bone marrow involvement, and either presence of≥ 2 cytogenetic abnormalities, or presence of specific cytogenetic abnormalities found in minimum 5 R-
CHOP-treated patients and associated with significant poor prosnosis in the univariate analysis (+3, −17, abnormalities at 14q32, 3q25-q27, 19p13, 8q24, 7q22, 1q21-q23,
18q21, 19q13, 9q34, 22q11, 11q23-q25, 12q22-q24, 16q22-q24, and deletion 6q). The stepwise selection procedure was used to select variables in the final models.
Abbreviations: CI, confidence interval; HR, hazard ratio; NS, not significant.
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loma. The disadvantages of cytogenetic testing using tis-
sue samples include the necessity of laborious tissue
preparation, the presence of fuzzy chromosomes, a lack
of metaphase cells, and contamination. Because BM
studies are a standard process of DLBCL staging, the use
of BM samples for additional conventional cytogenetic
testing is easily applicable. There are two major possible
advantages associated with the cytogenetic testing of BM
samples in DLBCL patients: an increased sensitivity for
detecting BM involvement in DLBCL and the informa-
tion provided by the chromosomal abnormalities foundin the BM. In this study, we analyzed retrospective data
from a large series of patients to analyze both possible
advantages.
One major difficulty in the decision about whether to
perform cytogenetic testing on BM specimens is caused
by the absence of BM involvement in many DLBCL pa-
tients. Even in patients with BM involvement, the
lymphoma cells may be obscured by the more abundant
normal hematopoietic cells [5,6,19,20]. In our data, 8.8%
of the total patients exhibited multiple chromosomal ab-
normalities, and 1.3% of the patients were diagnosed
with BM involvement on the basis of cytogenetic results
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were BMIhisto
+, the detection rate of significant cytogen-
etic abnormalities in BM specimens was not negligible.
Because karyotyping is based on metaphases, the num-
ber of metaphases with cytogenetic abnormalities does
not necessarily represent the proportion of cells within
BM cells [21]. Karyotyping may be a sensitive method,
because a small clone with proliferative advantage over
normal cells may be identified by karyotyping.
The interpretation of data from patients with a single
abnormality can be difficult because the abnormality
does not necessarily originate from lymphoma cells. In
our study, single aneuploidies demonstrated only a 10%
concordance rate with histologic examination, which in-
dicates that a single aneuploidy cannot be the definite
evidence for presence of lymphoma cells. In addition,
patients with single aneuploidies had less aggressive dis-
ease than normal karyotype cases with histologic in-
volvement and presented no significant differences in
prognosis. Therefore, the presence of a single numerical
abnormality cannot be an indicator of the advanced disease
and a poor prognostic factor. In fact, loss of chromosome Y
is a well-known normal age-related phenomenon in elderly
males [22]. Although monosomy 21 can be detected as a
sole cytogenetic abnormality in a variety of hematologic
disorders, the random loss of chromosome as an artifact of
cell culture or slide preparation can cause this abnormality
[23]. Single structural abnormalities also presented lower
concordance rate with histologic BM involvement. There
were 2 patients with del(20q) without histologic evidence of
BM involvement. Although these patients did not presented
cytopenia or morphologic dysplasia, previous studies
reported that myelodysplastic syndrome associated with
isolated del(20q) can commonly present with minimal mor-
phological dysplasia [24]. There were a patient with dupli-
cation of Y chromosome and patients with balanced
translocation, which may be constitutional chromosomal
aberrations [25,26]. However, some single abnormalities
can represent a primary event in lymphomagenesis. In this
study, single structural abnormalities such as t(14;18)(q32;
q21) or t(3;14)(q27;q32) can be reasonably regarded as orig-
inated from lymphoma cells considering their well-known
chromosomal loci and their concordant histologic BM re-
sults. Because of the small number of analyzed cases, it was
hard to make convincing conclusion about the significance
and prognostic impact of these single abnormalities in this
study. When these abnormalities are detected, cautious BM
examination with other ancillary tests may be needed. Fur-
ther studies will be needed for more clear conclusion and
to make a guideline on the appropriate interpretation of
ambiguous cytogenetic abnormalities.
Most importantly, this study demonstrated that BM
cytogenetic results have a powerful prognostic signifi-
cance that is independent of BM histology. The presenceof ≥ 2 chromosomal abnormalities was associated with
very poor prognosis among both patients with and with-
out histologic BM involvement. This finding confirms
that a BM cytogenetic result is a stronger prognostic
predictor than histologic BM involvement. The signifi-
cant prognostic effect of cytogenetic abnormalities was
observed in patients that had been stratified according
to their IPI risk scores, especially for patients with high
intermediate risks.
The chromosomal abnormalities observed in this study
were nonrandom and recurrent, implying that they may
belong to the recurrent lymphomagenesis pathway [27].
There have been previous reports of high frequencies of
many of these abnormalities, including rearrangements at
14q32, 1p, 3q27, 8q24, 11q23-q25, and 18q21-q23; dupli-
cations at 1q; and deletions at 6q. The most common nu-
merical abnormality in DLBCL, trisomy 18, has also been
frequently reported in many other B-cell neoplasms
[28,29]. The 14q32/IGH rearrangement, which was the
single most common abnormality in the present study, is
frequently observed in all B-cell neoplasia [30-36]. Be-
cause 14q32/IGH rearrangements mainly involve balanced
translocations, these rearrangements can be detected only
by G-banding, not through array methods [37-41].
In our data from patients with multiple abnormalities,
which specific loci presented abnormalities was a more
significant prognostic factor than the number of abnor-
malities. Several abnormalities, including aberrations at
16q22-q24, 6p21-p25, 12q22-q24, 11q23-q25, 19q13,
1q21-q23, 8q24, and 19p13, and −17 appeared to be as-
sociated with a worse prognosis in the univariate ana-
lysis. The multivariate analysis demonstrated that several
chromosomal abnormalities including aberrations at
19p13, 7q22, 12q22-q24, 18q21, and 16q22-q24 are inde-
pendent adverse prognostic factors for survival among
DLBCL patients with BM involvement. In addition, ab-
normalities at 19q13, 12q22-q24, 19p13, and 8q24 were
associated with poor prognoses among R-CHOP treated
patients with BM abnormalities. Because of the small
number of patients having each specific cytogenetic ab-
normality, and the high variability of the cytogenetic ab-
normalities, to make clear conclusion about the
prognostic importance of each specific chromosomal
loci might be difficult. However, we considered a recur-
rent cytogenetic abnormality with a high statistical sig-
nificance, such as abnormalities at 19p13 can be a
potentially important target for further investigation.
Aberrations in chromosome 19 have been reported in
several previous series of DLBCL cases, although their
prognostic impact was not explored [30,33,35,36,40-42].
The identity of the specific gene on 19p13 that is associ-
ated with DLBCL is not yet known; however, TCF3 has
been reported to be associated with acute lymphoblastic
leukemia [43], and microRNA (miRNA) genes have been
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recent study using array-CGH and SNP-chip analyses
reported that recurrent deletions of the tumor suppres-
sor genes, TNFSF7 and TNFSF9 at the 19p13.3 region
were observed in DLBCL and Burkitt lymphomas [45].
These genes may play an important role in the patho-
genesis of DLBCL leading to disease progression and
BM involvement. The MYC/8q24 rearrangement, which
has been reported to be associated with a poor prognosis
when detected in tissues using FISH at the time of diag-
nosis [46-49], was independently associated with disease
progression in this study. The nonrandom nature of the
observed chromosomal abnormalities and their associ-
ation with prognosis suggest that investigations into the
clonal evolution of DLBCL could provide useful insights
into the pathogenesis of this disease.
Our study has several limitations. First, this study was
performed retrospectively, and the patients had under-
gone heterogeneous therapies. Second, the evaluations
of the cell of origin and CD5 positivity were limited.
Third, several BM-related prognostic factors, including
the extent and histologic characteristics of the BM
involvement, could not be investigated [3,4,50,51].
However, considering the comparable results of the
BMIhisto
+ and BMIhisto
− cases, it could be suggested
that cytogenetic aberrations are a stronger prognostic
factor than other BM-related factors.
The results of this study may be representative of the
major characteristics of the BM chromosomal abnormal-
ities in the Korean DLBCL population, considering the
large size of our data series. A larger series of international
investigations may be needed to characterize and confirm
the prognostic significance of the BM cytogenetic aberra-
tions in DLBCL patients from other ethnic groups, con-
sidering the variety of external genotoxic agents that can
cause chromosomal changes and the diversity of host sus-
ceptibility factors to chromosomal breaks. Results from
classic cytogenetics can guide the design of additional
studies using other techniques, such as FISH or arrays.
In conclusion, the conventional cytogenetic testing of
BM may provide essential information for newly diag-
nosed DLBCL patients. We suggest that cytogenetic test-
ing of BM samples should be integrated with DLBCL
staging apart from histologic examination, and more ef-
fective therapeutic strategies should be developed. In
addition, frequently affected cytogenetic regions, such as
19p13, must be intensively investigated to characterize
the underlying molecular pathogenesis of DLBCL.
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